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ABSTRACT
Human Silent Information Regulator Type 1 (SIRT1)
is an NAD
+-dependent deacetylase protein which is
an intermediary of cellular metabolism in gene
silencing and aging. SIRT1 has been extensively
investigated and shown to delay senescence;
however, less is known about the regulation of
SIRT1 during aging. In this study, we show that the
peroxisome proliferator-activated receptor-c
(PPARc), which is a ligand-regulated modular
nuclear receptor that governs adipocyte differenti-
ation and inhibits cellular proliferation, inhibits
SIRT1 expression at the transcriptional level.
Moreover, both PPARc and SIRT1 can bind the
SIRT1 promoter. PPARc directly interacts with
SIRT1 and inhibits SIRT1 activity, forming a
negative feedback and self-regulation loop. In
addition, our data show that acetylation of PPARc
increased with increasing cell passage number.
We propose that PPARc is subject to regulation by
acetylation and deacetylation via p300 and SIRT1 in
cellular senescence. These results demonstrate a
mutual regulation between PPARc and SIRT1 and
identify a new posttranslational modification that
affects cellular senescence.
INTRODUCTION
Diverse genetic and environmental factors affect longevity
in a wide variety of organisms (1). Cellular senescence,
also known as replicative senescence, is a process
through which cells lose their proliferative potential after
a limited number of population doublings (PDs). This is
accompanied by a speciﬁc set of changes including growth
cessation, morphologic changes and appearance of
senescence-associated beta-galactosidase (SA- -gal)
activity.
SIRT1 (sirtuin 1) (Sir2 histone deacetylase) is an im-
portant determinant of longevity that plays a role in
life-span regulation in diverse species (2–5). Caloric re-
striction (CR) can greatly increase life span in mammals
(6), and the mammalian Sir2 ortholog, SIRT1, may
mediate this effect of CR by affecting peroxisome
proliferator-activated receptor g (PPARg), PGC1-a, p53,
forkhead transcription factors (FOXO) and p300, just to
name a few (7–11). In addition, SIRT1 activity has also
been associated with tumorigenesis (12). As such, it is con-
ceivable that SIRT1 may be a ‘double-edged sword’ that
requires tight regulation. Despite the fact that there has
been extensive study of SIRT1 function, the regulation of
SIRT1 is less well understood.
PPARg is a transcription factor that belongs to the
ligand-activated nuclear receptor superfamily. PPARg
plays an important role in the induction of cellular differ-
entiation and the inhibition of cell growth by promoting
cell-cycle arrest (13,14). In addition, PPARg promotes
cellular senescence by inducing p16
INK4a (CDKN2A),
which is an important cell-cycle inhibitor (15). A
previous study in our laboratory showed that SIRT1
promoted cell proliferation and antagonized cellular sen-
escence in human diploid ﬁbroblasts (16).
Considering our previous work and that of others, we
asked the question whether ligand-activated PPARg regu-
lates SIRT1 expression at the transcriptional level or the
protein level, and how it functions in the cell. Our results
demonstrated that SIRT1 complexes with PPARg via its
core deacetylase catalytic activity domain, and both
SIRT1 and PPARg bind directly to the promoter of
SIRT1 itself and thus control homeostatic SIRT1
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of PPARg is regulated through deacetylation by SIRT1.
This association of SIRT1 and PPARg together with
the transcriptional modulation of SIRT1 appears to be im-
portant in the senescence process controlled by PPARg.
This study therefore shows evidence that the longevity-
regulating protein SIRT1 is under the direct control of
PPARg and that the role of PPARg in regulating
cellular senescence involves a complex feedback loop
including SIRT1. Our results also suggest that PPARg
acetylation may play an important role in regulation of
SIRT1 during cellular senescence.
MATERIALS AND METHODS
Plasmids, antibodies and regents
The SIRT1 promoter was isolated by polymerase chain
reaction (PCR) and spanned  1048 to+900bp, which con-
tained the entire SIRT1 promoter CpG island. The
promoter was inserted into the Bgl II/Hind III sites of the
pGL3 basic luciferase expression vector (Promega). A
series of fragments from this sequence were PCR-ampliﬁed
or treated with restriction endonucleases. Expression
plasmids encoding human SIRT1 (pBABE-SIRT1),
human SIRT1 H363Y (deacetylase domain mutation)
andhumanPPARg(pBABE-PPARg)were constructed ac-
cording to the manufacturer’s guideline. The upstream (en-
compassing the coding region for amino acids 1–253) and
downstream (encompassing the coding region for amino
acids 496–747) regions of pcDNA3.1-Myc-SIRT1 were
constructed by PCR ampliﬁcation of the pcDNA3.1-
SIRT1 plasmids, using the primers 50-ATGGCGGACGA
GGCGGCCCT-30;5 0-AAGTTTGGCATATTCTTGCAC
TCTTGCAGT-30;5 0-GAATATGCCAAACTTGAATAT
GCCAAACTT-30 and 50-GATACTAAACAAACTACCT
ATCAAG-30, respectively. These two PCR products were
mixed, annealed and ampliﬁed in a third PCR reaction
using primers 50-GGATCCATGGCGGACGAGGCGG
CCCT-30 and 50-GCGGCCGCGATACTAAACAAACT
ACCTA-30. The ﬁnal PCR product encoding
Myc-SIRT1 was cut with BamH I/Not I, and ligated
into pcDNA3.1. Site-directed mutagenesis was performed
using the QuikChange protocol (Stratagene). Antibodies
which were used included anti-SIRT1 (Abcam ab32441),
anti-Sir2 (Upstate 07-131), anti-p300 (Upstate 05-257),
anti-PPARg (Upstate 07-466), anti-actin (Abcam
ab11003), anti-FLAG antibody (Sigma M2), anti-Myc
(Santa Cruz TA-01) and anti-acetyl-lysine (Cell
Signalling). The SuperSignal west picochemiluminescent
substrate was obtained from Pierce Biotechnology
(Rockford, IL). Sirtinol (Sigma).
Cell lines and animals
Human embryonic lung diploid ﬁbroblast 2BS cells
(obtained from the National Institute of Biological
Products, Beijing, China) were originally isolated from
female fetal lung ﬁbroblast tissue and have been
characterized previously (17). 2BS cells are considered to
be young at PD30 or below and to be fully senescent at
PD55 or above. Human WI-38 embryonic lung diploid
ﬁbroblast cells (ATCC number: CCL75) were obtained
from the Chinese Academy of Sciences (Shanghai,
China). WI-38 cells are considered to be young at PD25
or below and to be fully senescent at PD50 or above. 2BS
cells, WI-38 cells, HeLa cells and Phoenix cells were main-
tained in Dulbecco’s modiﬁed Eagle’s medium (DMEM),
with 10% fetal calf serum (Sigma) at 37 C in a 5% CO2
atmosphere. Young (3–4 months) and aged (18–22
months) BALB/c mice were maintained on a 12-h light/
dark cycle with food and water available ad libitum. All
animal studies were performed in accordance with the
guidelines set forth by the Peking University Animal
Ethics Committee.
Retroviral infection was performed as described (18).
In experiments presented in Figure 7, Phoenix cells
were transfected with either pBABE, pBABE-SIRT1,
pBABE-SIRT1H363Y, pSUPERretro (Oligoengine) or
pSUPERretro-PPARg RNAi (50-GCCCTTCACTACTG
TTGAC-30) (19) using lipofectamine 2000 (Invitrogen).
After 48h of transfection, the retrovirus containing
medium was collected, ﬁltered, treated with polybrene
(1mg/ml) and used to infect young 2BS target cells.
Infected cells were selected for resistance to puromycin
(2.5mg/ml) and G418 (200mg /ml), and then pooled.
Luciferase reporter assay
HeLa cells were cultured in DMEM supplemented
with 10% fetal bovine serum (FBS) and were transfected
with the indicated plasmids by using Lipo transfection
reagent (Invitrogen). Cell lysates were prepared with the
Dual Luciferase reporter assay kit (Promega Corp.,
Madison, WI, USA). A rennilla plasmid was included
to control for efﬁciency of transfection. After transfection,
the cells were incubated in DMEM supplemented
with 10% FBS for 42h. Luciferase activity was
measured and normalized using renilla activity in
the same sample. Luciferase and renilla assays were per-
formed in triplicate, and experiments were repeated at
least three times.
Immunoprecipitation, glutathione S-transferase pull-down
and western blot
Cells were lysed in modiﬁed RIPA nuffer [1mM
ethylenediaminetetraacetic acid EDTA, 150mM NaCl,
1mM NaF, 1mM Na3VO4, 1m MPMSF, 0.25%
deoxycholic acid (sodium salt), 1% NP-40, 1mg/ml
leupeptin, 1mg/ml aprotatin, 150mM Tris–HCl at pH
7.4] centrifuged for 10min at 14000g and the insoluble
debris was discarded. Protein concentration of each
sample was determined by BCA Protein Assay Reagent
(Pierce). Cell lysate (500mg protein) was immunopre-
cipitated using the indicated antibodies overnight,
and 50ml of protein A-agarose beads were added to
the lysate and rotated at 4 C for 2h. The beads
were washed extensively with cold phosphate-buffered
saline (PBS), boiled in sodium dodecyl sulfate (SDS)
sample buffer, fractionated with SDS-polyacrylamide
gel electrophoresis (PAGE) and probed with the corres-
ponding antibodies. To evaluate for SIRT1-PPARg
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of SIRT1-PPARg plasmids using calcium chloride
and cells were lysed for immunoprecipitation (IP)
after 48h.
Glutathione S-transferase (GST) and the GST-fusion
proteins GST-PPARg were produced in Escherichia coli
DH5a and bound to glutathione-Sepharose beads accord-
ing to the manufacturer’s instructions (Amersham
Pharmacia Biotech).
Transfection of short-interfering RNA
The short-interfering RNA (siRNA) sequences targeted
human PPAR  (GeneID: 5468) or SIRT1 (GeneID:
23411), and the transcripts sequences were 50-GCCCTT
CACTACTGTTGACtt-30 (19) or 50-CGTCTTATCCTC
TAGTTCTtt-30 (20). A scrambled sequence referred to a
si-NC was provided by company and used as negative
control (NC). Cells were transfected with siRNA using
lipofectamine-RNAiMAX according to the manufactur-
er’s instructions (Invitrogen).
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were
performed using the Chromatin Immunoprecipitation
Assay kit (Upstate, New York, NY, USA) according to
manufacturer’s instruction. In brief, 1 10
6 cells were
cross-linked by adding formaldehyde directly to cell
culture media and incubating for 10min at 37 C.
Cells were washed twice with cold PBS, and cells were
scraped and resuspended in 200ml of SDS lysis buffer.
Chromatin was then sonicated to an average length
of 0.5kb with three 30-s pulses at maximum power.
Chromatin extracts were diluted 10-fold in dilution
buffer and preincubated for 30m at 4 C with 50mlo f
Salmon Sperm DNA/protein A-agarose. Twenty micro-
liters of diluted supernatant was kept for isolation
of input DNA and quantitation of the DNA in different
samples. After pelleting the agarose by brief centrifuga-
tion, 2mg of anti-SIRT1 antibody or anti-PPARg
(test group) or 2mg of anti-b-actin (unrelated antibody
control) was added to the supernatant fraction and
incubated overnight at 4 C with rotation. In addition,
we performed an IP omitting the antibody by incubating
the supernatant fraction with Salmon Sperm
DNA/protein A-agarose for 1h at 4 C. Fifty microliters
of Salmon Sperm DNA/protein A-agarose was then
added, and the mixture was incubated for 1h at 4 Ct o
collect the antibody/antigen–DNA complex. The chroma-
tin bound to the protein A-agarose beads was eluted
in 500ml of freshly prepared elution buffer (1% SDS,
0.1M NaHCO3). After reversing the cross-linking, the
samples were deproteinized and phenol–chloroform-
extracted, and DNA was ethanol-precipitated using
glycogen as a carrier. Pellets were resuspended in 50ml
of TE buffer (10mM Tris–HCl, 1mM EDTA, pH 8.0)
for PCR analysis.
In re-ChIP experiments, endogenous PPARg, SIRT1or
p300-chromatin complexes from HeLa cells were ﬁrst
immunoprecipitated using PPARg, SIRT1or p300
antibodies. The complexes were eluted by incubation for
30min at 37 C in 10mM DTT, diluted 10 times in re-ChIP
buffer (1% Triton X-100, 2mM EDTA, 150mM NaCl,
20mM Tris–HCl at pH 8.0) and subjected to a second
ChIP. Coprecipitated chromatin was analyzed by PCR
for the presence of SIRT1 promoter DNA between
 592 and  163bp upstream of the SIRT1 ATG
start codon using 50-CAACGTATTTCAGGGAGCT-30
( 592) and 50-CCACAACACTACGGGTCA-30 (–163)
primers.
Real-time PCR methods and data analysis
Total RNA was isolated from HeLa,WI-38 and 2BS cells
using an RNeasy Mini kit (Qiagen) according to the
manufacturer’s instructions and subjected to reverse tran-
scription followed by both quantitative real-time and
semi-quantitative PCRs using the High Capacity cDNA
Archive Kit (Invitrogen, Carlsbad, CA, USA), according
to the manufacturer’s protocols. Real-time PCR was per-
formed using Assays-on-Demand Gene Expression
Products (Applied Biosystems, Foster City, CA, USA)
according to the manufacturer’s instructions, with minor
modiﬁcations and run on an ABI 7300 Real-time PCR
System (Applied Biosystems). Each PCR was assembled
using 96-well MicroAmp Optical plates (AB Applied
Biosystems) with a total volume of 15ml containing
1.5ml cDNA templates, 1mM of each primer and 17.5ml
of 2 SYBR Green Master Mix and brought to ﬁnal
volume with RNase-free water. Thermal reaction cycles
of 50 C for 2min, 95 C for 10min and 40 repetitions
of 95 C for 15s and 60 C for 1min were used.
Real-time PCR data were analyzed using the CT
method, normalizing the Ct values of the indicated
gene to the Ct values of GAPDH relative to a control
sample.
Site-directed mutagenesis
Substitution mutations were generated using the
QuikChange mutagenesis kit (Stratagene) according to
the manufacturer’s instructions. Synthetic oligonucleo-
tides that contained the desired bases were used. The
sequence of mutations for nucleotides at positions  337
and  336 (GG-CC) of the 50-ﬂanking region of the SIRT1
promoter was 50-CCGGCGGTAGTGATTTACCGTCA
GTTTGAAAGAGAAGTTG-30 (GG-CCmutation
underlined); DNA that incorporated the desired muta-
tions was transferred into XL1-Blue supercompetent
cells. Plasmid DNA was prepared and mutations were
conﬁrmed by sequencing.
SA-b-gal analysis
For SA- -gal staining, the stably transfected cells
and normal 2BS cells were washed twice with PBS, ﬁxed
for 3–5min at room temperature in 3% formaldehyde
and washed again with PBS. Cells were then incubated
overnight at 37 C without CO2 in a freshly prepared
staining buffer (1mg/ml X-gal, 40mM citric acid/sodium
phosphate, pH 6.0, 5mM potassium ferrocyanide, 5mM
potassium ferricyanide, 150mM NaCl, 2mM MgCl2) (21).
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To assess the level of PPARg acetylation, HeLa cells
were transfected with a Flag-PPARg expression vector
and where indicated, an expression vector encoding
p300. Acetylation status was determined by immunopre-
cipitation of 1mg of protein lysate in RIPA Lysis buffer
using an antibody directed against the Flag-epitope tag.
Levels of acetylated PPARg were subsequently assessed
with an anti-acetyl lysine antibody (Cell Signaling). After
24h transfected cells were treated with 100mM Sirtinol
[Sigma; dissolved in dimethyl sulfoxide (DMSO)]. Cells
were incubated with Sirtinol or transfected with
SIRT1-targeting siRNA oligonucleotides for the last
24h prior to harvest, after which they were used for
subsequent experiments. For the in vitro deacetylation
reaction, immunoprecipitated PPARg was incubated
with IP-puriﬁed SIRT1.This reaction was performed in
20mM Tris, pH 8.0, for 2h at 30 C in the presence or
absence of the indicated concentration of nicotinamide
adenine dinucleotide (NAD) or nicotinamide. After incu-
bation with IP-puriﬁed SIRT1, the level of acetylated
PPARg was determined by western blot analysis and
the protein was identiﬁed using an anti-acetyl lysine
antibody.
Statistical analysis
Analysis of variance (ANOVA) was performed where
appropriate, followed by the Student’s t-test. In all cases,
P-values <0.05 were considered signiﬁcant.
RESULTS
Expression and transcription levels of SIRT1 declined in
senescent WI-38 cells and in lung, fat and heart tissues
from senescent Balb/c mice
The replicative life span in yeast cells is sensitive to the
expression level of SIR2 (2). Using WI-38 cells (Normal
human ﬁbroblast cell line) as a known cellular model of
replicative senescence, we evaluated the level of SIRT1
protein in young (18PDs) and senescent (45PDs) WI-38
cells by western blot analysis. The SIRT1 expression level
in cell extracts decreased as the number of cell PDs
increased, as shown in Figure 1A. Similarly, we
compared the level of SIRT1 in tissues from young adult
Balb/c mice (4 months of age) to those of older Balb/c
mice (18–24 months). As shown as in Figure 1C, SIRT1
levels decreased signiﬁcantly with age in the lung, fat and
heart from these mice.
To determine whether changes in the SIRT1 protein
level are due to changes in SIRT1 transcription, we
measured the level of SIRT1 messenger RNA (mRNA)
in the same cells and tissues (including lung, fat and
heart samples) via quantitative real-time reverse
transcriptase-PCR (RT-PCR). We found a signiﬁcant
correlation between the amount of SIRT1 transcript
and the age of the animal in these tissues. These
results, which are shown in Figure 1D, are consistent
with our ﬁndings in cultured cells (Figure 1B). Our
results suggested that the regulation of SIRT1 might be
at the transcription levels.
PPARc directly regulates SIRT1 transcription
As the SIR2 expression level critically inﬂuences life ex-
pectancy of both yeast and worm species (2,22), homeo-
static regulation of this protein would seem essential. We
thus wanted to determine whether PPARg can mediate
such homeostasis through direct transcriptional regulation
of the SIRT1 gene. Western blot analysis revealed that
PPARg over expression or treatment with troglitazone,
which is a PPARg agonist, signiﬁcantly reduced expres-
sion of SIRT1 in HeLa cells, and the greatest decrease was
observed when cells both overexpressed PPARg and were
treated with troglitazone (Figure 2A, upper panel).
To further verify this ﬁnding, we silenced the PPARg
gene and examined SIRT1 protein levels. Western blot
assay revealed markedly enhanced SIRT1 expression in
the PPARgsiRNA-transfected cells compared with NC-
transfected cells (Figure 2A, lower panel). Moreover,
PPARg-agonist treatment did not reduce SIRT1 levels
in PPARgsiRNA-transfected cells (Figure 2A, lower
panel).
Could the observed reduction in the level of SIRT1
have been caused by changes at the transcription level?
To test this, we analyzed the levels of SIRT1 mRNA in
PPARgsiRNA -transfected cells. The results are shown
in Figure 2B for (NC)-transfected and PPARgsiRNA
-transfected cells. In parallel with protein levels, the
level of SIRT1 mRNA was reduced by PPARg in a
ligand-dependent manner as measured by real-time
quantitative PCR. Taken together, these results showed
that the changes in the level of SIRT1 protein occur at
the transcription level.
To further characterize these changes, we cloned a
1.9-kb SIRT1 promoter fragment which contained the
PPARg-binding site’s putative peroxisome proliferator
response element (PPRE) as described in detail below, to
construct a luciferase reporter (Luc). Successive deletions
of the SIRT1 promoter revealed that the activity of the
1405- and 1246-bp fragments of the SIRT1 promoter
increased four times relative to that of the plasmid alone
in HeLa cells (Supplementary Data, Figure 2). It was of
interest that both these two regions contain PPRE.
Subsequently, we analyzed the effects of PPARg on the
expression of the SIRT1 reporter gene, in which the
luciferase gene is driven by an SIRT1 promoter. HeLa
cells were transfected with various combinations of
plasmids that expressed pcDNA3.1, pcDNAPPARg or
oligoPPARgsiRNA, or an NC together with both
wild-type SIRT1-Luc and mutant SIRT1-Luc. Cells were
then treated with troglitazone (20mM). Reporter activity
was reduced by treatment with PPARg agonist, and this
activity was 5.9-fold lower in cell lysates that contained
PPARg compared with those that did not contain PPARg
in the presence of troglitazone (Figure 2C). Mutation of
SIRT1-Luc resulted in incomplete reduction of SIRT1
promoter activity in the presence or absence of
troglitazone (Figure 2C). Identical results were obtained
in cells transfected with PPARgsiRNA (Figure 2D). Thus,
Nucleic Acids Research, 2010,Vol.38, No. 21 7461ligand-activated PPARg directly regulates SIRT1
transcription.
SIRT1 interacts with PPARc through its deacetylase
catalytic domain
Protein–protein and DNA–protein interactions were
next analyzed to further evaluate the relationship and
interaction of SIRT1 and PPARg. Cellular interaction
between SIRT1 and PPARg was conﬁrmed by use of
the IP assay. HeLa cells were transfected with epitope-
tagged constructs encoding Myc-SIRT1 or Flag-PPARg.
IP with anti-Myc antibody, and subsequent western
blotting (WB) with anti-PPARg or anti-Flag antibody
(Supplementary Data, Figure 3A) showed that SIRT1
can interact with PPARg in vivo. This was also conﬁrmed
by reciprocal IP (Supplementary Data, Figure 3B).
We also transiently expressed an epitope-tagged mutant
form of SIRT1 (SIRT1H363Y) together with PPARg
in HeLa cells. This mutant allele speciﬁes an amino acid
substitution at residue 363 of the SIRT1 protein, replacing
the histidine normally found in this position by tyrosine.
This substitution would result in alteration of the highly
conserved catalytic site of the SIRT1 protein, the loss
D
C
Y             S  
WI-38 cells 
Y           S  
SIRT1 
-actin 
F
o
l
d
 
c
h
a
n
g
e
 
o
f
 
S
I
R
T
1
 
m
R
N
A
 
Y           S   Y          S   Y            S  
F
o
l
d
 
c
h
a
n
g
e
 
o
f
 
S
I
R
T
1
 
m
R
N
A
 
F
o
l
d
 
c
h
a
n
g
e
 
o
f
 
S
I
R
T
1
 
m
R
N
A
 
F
o
l
d
 
c
h
a
n
g
e
 
o
f
 
S
I
R
T
1
 
m
R
N
A
 
SIRT1 
-actin 
SIRT1 
-actin 
SIRT1 
-actin 
Lung
Fat
Heart
YS
AB
Lung  Fat  Heart 
b
b
b
b
Figure 1. Alterations of SIRT1 mRNA and protein expression levels were determined in senescent WI-38 cells and animal tissues. (A) Western blot
of extracts from young-15PDs (Y) and senescent-45PDs (S) WI-38 human lung ﬁbroblasts, with actin as a loading control. Western blotting was
performed using speciﬁc antibodies against SIRT1 as indicated. (B) Quantitative real-time PCR analysis of SIRT1 mRNA levels isolated from Y or S
WI-38 cells. GAPDH transcript was used as a control. The data presented are average values obtained from triplicate data points from a repre-
sentative experiment (n=3), which was repeated three times with similar results. (C) Western blot analysis of SIRT1 expression in extracts from
lung, fat and heart tissues in young (Y) and senescent (S) Balb/c mice, with actin as a loading control (n=3 per group). (D) Real-time PCR analysis
of SIRT1 mRNA derived from lung, fat and heart tissues in young and senescent Balb/c mice, GAPDH transcript was used as a loading control
(n=3 per group).
7462 Nucleic Acids Research, 2010,Vol.38, No. 21of its deacetylase activity and the acquisition of a
dominant-negative function. In contrast to the interaction
of wild-type protein seen with PPARg, analysis with
SIRT1H363Y resulted in reduced levels of
co-immunoprecipited PPARg [Supplementary Data,
Figure 3A (lower panel) and B]. As shown in
Supplementary Data Figure 3A and B, IP of PPARg
from lysates demonstrated association with wild-type
SIRT1, but this association was reduced by SIRT1H363Y.
To conﬁrm that this reﬂected a direct physical interaction,
we employed an in vitro interaction assay with recombin-
ant GST–PPARg. Based on the result of this GST
pull-down assay (Figure 3A), SIRT1 interacts directly
with PPARg in vitro, which raises the possibility that
PPARg may be a substrate for SIRT1 deacetylase.
Therefore, to identify the region of SIRT1 that is respon-
sible for the SIRT1–PPARg interaction, we generated a
deletion mutant of SIRT1 designated for this study
as Myc-SIRT1. This mutant consists of ligation
of the N-terminal and C-terminal sequences without
the catalytic core domain. Our results showed that
the SIRT1 catalytic domain is required for PPARg
to recruit SIRT1 (Figure 3B). Collectively, these
data indicate that the SIRT1 catalytic domain is neces-
sary and sufﬁcient for the interaction of PPARg and
SIRT1.
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PCR reactions (mean±SD). (C) HeLa cells were transfected with expression plasmids pcDNA3.1 (vector) or pcDNA–PPARg (PPARg) together
with wild-type SIRT1–Luc or mutant SIRT1–Luc. (D) HeLa cells were transfected with NC and PPARgsiRNA together with wild-type SIRT1–Luc.
Cells were subsequently treated with 20mM troglitazone. Luciferase activity was then measured 48h after treatment. Values are the mean±.SD of
triplicate data points from a representative experiment (n=3), which was repeated three times with similar results.
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promoter template allowing SIRT1 to self-regulate
Using the ChIP assay, we found that endogenously ex-
pressed PPARg speciﬁcally binds to the PPRE cluster on
the SIRT1 promoter in HeLa cells (Figure 4A). As we had
shown that SIRT1 interacts with PPARg through its cata-
lytic core domain, we speculated that these two proteins
might form a functional complex in which SIRT1 may
participate in the control of its own transcription.
Indeed, the ChIP assay using SIRT1 antibody indicated
that endogenous SIRT1 was present on its own promoter
in HeLa cells (Figure 4A). This raised the possibility that
exogenous SIRT1 inﬂuences endogenous SIRT1 transcrip-
tion by forming a self-regulating feedback loop (Figure 4B
and C). To conﬁrm this hypothesis, we performed sequen-
tial ChIP assays, consisting ﬁrst of a round of ChIP with
PPARg antibody, followed by elution of the pull-down
complex, and a second round of immunoprecipitation
with SIRT1 antibody. The bound DNA was then
ampliﬁed for 50 region SIRT1-binding sites. Sequential
ChIP assays using SIRT1 antibody ﬁrst, followed by
PPARg antibody, were also carried out. In both of these
ChIP-upon-ChIP assays, endogenous PPARg and SIRT1
co-localized on the 50 SIRT1 promoter site, suggesting
that PPARg recruits SIRT1 to SIRT1 promoter
(Figure 4D). As NC, PCR ampliﬁcation using GAPDH
primers failed to yield a signiﬁcant signal (Figure 4A
and D). Moreover, dose-dependent knockdown of
PPARg using SIRT1 antibody signiﬁcantly reduced the
SIRT1 ChIP signal, conﬁrming that the binding of
SIRT1 to its own promoter is mediated by PPARg
(Figure 4E). Neither the unrelated antibody control
(b-actin) nor the NC (no antibody sample) had ampliﬁca-
tion products. Taken together, these data suggested that
SIRT1 and PPARg can form a stable transcription in-
hibiting complex that binds to the SIRT1 promoter and
directly repress SIRT1 transcription.
SIRT1 binds p300 and deacetylates PPARc in vivo
and in vitro
Previous ﬁndings have indicated that PPARg levels
remain constant in young and senescent cells, but do not
explain why the transcriptional activity of PPARg in-
creases in senescent cells. However, posttranslational
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SDS–PAGE and probed with monoclonal SIRT1 antibody (upper panel). The lower panel shows the result of probing with monoclonal GST
antibody. (B) HeLa cells were co-transfected with expression plasmids encoding Flag-tagged full-length PPARg and deletion mutants of SIRT1.
Immunoprecipitation and immunoblotting were performed 48h post-transfection as indicated (+, present; –, absent).
7464 Nucleic Acids Research, 2010,Vol.38, No. 21modiﬁcations are known to affect PPARg transcriptional
activity (15). Moreover, SIRT1 acting as a protein
deacetylase has been shown to deacetylate numerous tran-
scriptional regulators, including p53, AR and Era.
Therefore, as PPARg binds to the SIRT1 deacetylatase
catalytic domain, we were prompted to ask whether
human PPARg is also subject to lysine deacetylation.
This was tested, using IP with PPARg antibody from
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cells for ChIP analysis of the SIRT1 promoter using antibodies indicated. Precipitated DNA samples were ampliﬁed by PCR using a pair of primers
that amplify the –592bp to –163bp region with GAPDH as an unrelated primers control. (B) Luciferase reporter assay of the SIRT1 promoter in
SIRT1 transfected HeLa cells. HeLa cells were transfected with expression plasmids vector and SIRT1 as shown, together with SIRT1–Luc.
Luciferase activities were measured 48h after treatment. Values are the mean±SD of triplicate data points from a representative experiment
(n=3), which was repeated three times with similar results. (C) Real-time quantitative PCR analysis of endogenous SIRT1 mRNA levels in
SIRT1-transfected HeLa cells. HeLa cells were transfected with 10mg of vector or pCDNA3.1-SIRT1. GAPDH transcript was used as a internal
control. The error bar represents 1 SD. (D) ChIP-upon-ChIP assay showing the colocalization of PPARg with SIRT1 at the SIRT1 promoter.
Soluble chromatin was ﬁrst immunoprecipitated with rabbit SIRT1 antibody, and the eluted product was re-immunoprecipitated with rabbit PPARg
antibody. ChIP-upon-ChIP assay was also performed with immunoprecipitation in reverse order, that is, PPARg ChIP followed by SIRT1ChIP.
(E) PPARg recruites endogenous SIRT1 to its promoter in PPARg knockdown cells in a dose-dependent manner. Real-time quantitative PCR
veriﬁed the occurrence of recruitment. HeLa cells transfected with 10- or 20-nM PPARg siRNA (triangle) were processed for ChIP uing SIRT1
antibody. The PCR primers ampliﬁed the SIRT1 promoter region as indicated in (A). For negative controls, a sample that did not contain antibody
(No Ab) was immunoprecipitated, and antibody against b-actin was used as an unrelated antibody control.
Nucleic Acids Research, 2010,Vol.38, No. 21 7465HeLa cell lysate and an antibody that recognizes
acetyl-lysine for WB, and low levels of acetylated
PPARg were found (Figure5A, upper panel). Treatment
with sirtinol (100mM), which is a known inhibitor of
SIRT1 for 24h (23), led to a substantial increase in
PPARg acetylation. Similar results were obtained in
SIRT1siRNA-transfected cells, which resulted in reduced
levels of endogenous SIRT1 (Figure 5A, lower panel). It is
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Figure 5. SIRT1 deacetylates PPARg in vivo and in vitro.( A) Levels of PPARg acetylation are increased by the SIRT1 inhibitor sirtinol or siRNA
Knockdown of SIRT1. Where indicated, cells were treated for 24h with 100mM sirtinol or transfected SIRT1-targeting siRNA oligonucleotides for
24h. PPARg was immunoprecipitated (IP) from protein lysates using the Flag-epitope tag, and levels of acetylated PPARg were determined by
western blot (WB). (B) SIRT1 and p300 form complexes targeting SIRT1 to promoters. Untransfected HeLa cells were analyzed with sequential
ChIP assay using SIRT1 and p300 antibodies. The PCR primers ampliﬁed the SIRT1 promoter region from –592 to –163bp with GAPDH as an
unrelated primers control, and antibody against b-actin was used as an unrelated antibody control. (C) Expression of p300 stimulates PPARg
acetylation. Levels of acetylated PPARg were assessed in the presence of co-transfected p300 or an acetyltransferase-impaired mutant (p300DN).
(D) Levels of PPARg acetylation as a function of increasing amounts of transfected p300. (E) Endogenous PPARg was acetylated in response to
trichostatin A (TSA) for 8h. Endogenous PPARg was immunoprecipitated and subjected to western blot using antibodies directed against
acetylated-lysine residues. The blot was reprobed for the total amount of PPARg.( F) SIRT1 deacetylates PPARg in vitro in an NAD-dependent
manner. HeLa cells were transfected with expression plasmids encoding Flag-PPARg and p300, and PPARg was immunoprecipitated from protein
lysates using the Flag-epitope tag. SIRT1 from cells overexpressing SIRT1 was puriﬁed by immunoprecipitation and added to immunoprecipitated
PPARg for 1h in the presence or absence of indicated concentrations of either nicotinamide adenine dinucleotide (NAD) or NAM (nicotinamide).
Levels of acetylated PPARg were determined by western blot analysis using an antibody that recognizes acetyl-lysine (Ac-Lys) residues.
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mediated by acetyltransferases such as the protein p300,
and SIRT1 and p300 can interact (24) (also
Supplementary Data, Figure 4) to form a complex and
bind the SIRT1 promoter (Figure 5B). This raised the
possibility that PPARg could be acetylated by the
acetyltransferase p300. As shown in Figure 5C, the expres-
sion of p300 signiﬁcantly increased PPARg acetylation in
contrast to p300DN (an acetyltransferase-impaired
mutant-p300 dominant-negative form). Wild-type p300
strongly induced PPARg acetylation; however, an
enzymatically deﬁcient mutant p300 (DN) failed to do
so (Figure 5C). In fact, the level of PPARg acetylation
showed a clear correlation with the amount of transfected
p300. Subsequently, we tested whether SIRT1 could
deacetylate PPARg. As shown in Figure 5A and E,
sirtinol treatment strongly induced PPARg lysine acetyl-
ation but this effect was abolished by treatment with
trichostatin A (TSA), which is inhibitor of class I and II
histone deacetylases (HDACs) to which class III HDACs
(SIRT1) are not sensitive, indicating PPARg can be spe-
ciﬁcally deacetylated by SIRT1.
To determine whether PPARg can also be deacetylated
by SIRT1 in vitro, PPARg and p300 vector were
immunoprecipitated, and IP-puriﬁed SIRT1 was added
to these immunoprecipitates. As shown in Figure 5F, in
the presence of NAD puriﬁed SIRT1 was able to
deacetylated PPARg. However, addition of NAD did
not reduce PPARg acetylation in the absence of SIRT1
(Supplementary Data, Figure 5). Subsequently, as shown
in Figure 6, levels of acetylated PPARg in young 2BS or
WI-38 cells decreased signiﬁcantly in comparison with
those in senescent 2BS or WI-38 cells. Taken together,
these data indicate that PPARg was a deacetylase target
of SIRT1 and acetylation levels of PPARg elevated during
aging.
SIRT1 deacetylase activity inﬂuenced appearance of
senescence-associated features in 2BS cells
Cellular senescence is characterized by elevated levels
of endogenous b-gal activity at pH 6.0 which may
be identiﬁed by assay with X-gal which gives a
blue color reaction. Young (22 PDs) and senescent (61
PDs) 2BS cells were analyzed as controls. In order to
further verify that PPARg can modulate senescence via
SIRT1 deacetylase, we evaluated the role of SIRT1
deacetylase activity in mediating the senescence effects of
PPARg-shRNA in 2BS cells. Young 2BS cells infected
with both SIRT1 and PPARg-shRNA or SIRT1H363Y
and PPARg-shRNA were monitored (Figure 7A). The
results showed that 2BS with enhanced expression of
both wild-type SIRT1 and PPARg-shRNA displayed
lower frequency of SA-b-gal staining. However, there
were no signiﬁcant difference in SA-b-gal activity in the
mock vectors-infected cells as compared with SIRT1H363Y
and PPARg-shRNA-infected cells (Figure 7B). As
expected, both wild-type SIRT1 and PPARg-
shRNA-infected cells displayed young phenotypes
(Figure 7B). Taken together, these data indicate that
SIRT1 deacetylase activity caused resistance to cellular
senescence.
DISCUSSION
Senescence is the state or process of aging at the cellular
level, and this process is thought to be related both to
age-related diseases and to tumorigenesis (12). SIRT1 is
a member of the highly conserved gene family of sirtuins,
which were originally discovered in yeast as factors
required for gene silencing. Sirtuins have NAD
+-depend-
ent deacetylase and adenosine diphosphate (ADP)-ribosyl
transferase activity, which modulate the yeast replicative
life span by suppressing genome instability through chro-
matin modiﬁcation.
In this study, we explored the relationship between
changes in the level of the mammalian homolog SIRT1
and senescence both in culture and in the aging process in
mice. Both protein and mRNA levels of SIRT1, which is
the mammalian ortholog of SIR2, were signiﬁcantly
higher in young WI-38 cells than those in senescent cells.
Similarly, the amount of SIRT1 transcript is reduced in
older tissues of lung, heart and fat. Although it has been
reported that the level of SIRT1 mRNA does not decrease
signiﬁcantly with passage in IMR90 cells (25), it is likely
this is because a different cell line was used, leading to
differences in results. Sasaki et al. (25) reported no signiﬁ-
cant correlation between the amount of SIRT1 transcript
and the age of the animal for brain, testis and thymus
tested (25). In addition, we found SIRT1 transcript
levels do not signiﬁcantly differ in brain and kidney
(Supplementary Data, Figure 8). These inconsistent data
regarding SIRT1 transcript patterns might be to the
various roles of SIRT1 in different tissues during the pro-
gression of successive passages. Our ﬁndings suggest the
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Figure 6. Acetylation levels of PPARg in young and senescence 2BS and WI-38 cells. PPARg was immunoprecipitated from protein lysates using
PPARg antibody, and acetylation levels of PPARg were determined by western blot analysis using an antibody that recognizes acetyl-lysine (Ac-lys)
residues.
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Figure 8. Model for the role of PPARg in the cellular senescence. Reciprocal-type regulation of PPARg and SIRT1 is proposed for modulation of
cellular senescence in response to environmental factors. PPARg represses the transcription of SIRT1, SIRT1 deacetylates PPARg
posttranscriptionally and PPARg trans-inhibits SIRT1.
7468 Nucleic Acids Research, 2010,Vol.38, No. 21possibility that SIRT1 may be modulated at the transcrip-
tion level in the process of aging.
It is recognized that PPARg activation promotes
cellular senescence (15). This raised a question as to
whether activated PPARg serves to regulate SIRT1 and,
if so, whether PPARg and SIRT1 interact physically or
functionally, and how this association inﬂuences the
function of SIRT1 and PPARg during aging. Our results
demonstrated that SIRT1 is transcriptionally regulated by
PPARg, and also demonstrated that exogenous SIRT1
can inhibit endogenous SIRT1 at the transcription level.
Some studies have suggested that SIRT1 functions
by repressing PPARg activity (7). Our results show
that not only does SIRT1 function by repressing
PPARg, but conversely PPARg also represses SIRT1,
thus forming a negative feedback loop. At the same
time, this negative feedback effect and the fact
that PPARg and SIRT1 form a complex also raised the
possibility that SIRT1 exerts negative self-controlling
feedback.
More speciﬁcally, our results showed that SIRT1
complexes with PPARg via its catalytic domain, and
also showed that both SIRT1 and PPARg can bind to
the promoter of the SIRT1 gene and thus control homeo-
static SIRT1 expression in the process of aging. SIRT1 has
deactylase activity, and this strongly suggested the possi-
bility that regulation of PPARg activity is associated with
deacetylation. Point mutation at the catalytic domain
(H363Y) of SIRT1 greatly diminished the SIRT1–
PPARg interaction and demonstrated that an SIRT1
deletion mutant cannot bind to PPARg. Moreover, the
central deacetylase domain of SIRT1 is required for
PPARg binding. We were therefore led to evaluate
whether PPARg may be subject to acetylation modiﬁca-
tion and deacetylation by SIRT1, and found this is indeed
the case.
The mechanism by which acetylation alters PPARg
activity is not clear. However, it has been demonstrated
in general that acetylation can modify transcription factor
activity by increasing the DNA-binding activity, stability
or interaction with other transcription components.
Studies of SIRT1 have shown that its functions are ex-
tremely extensive, including interaction with important
nuclear receptors such as ERa and AR, and research
has demonstrated acetylation of ERa and AR increases
their transcriptional activation and protein stability (26–
30). To determine why the transcriptional activity of
PPARg increases as cell ages (14), we analyzed the acetyl-
ation state of PPARg in both young and senescent 2BS
and WI-38 cells. As expected, the levels of PPARg acetyl-
ation increased as cells aged (Figure 5). SIRT1 protein
directly interacts with PPARg to physically form a
complex, and this interaction might possibly control the
acetylation and deacetylation balance status of PPARg
protein, thus inﬂuencing PPARg transcriptional activity.
However, we cannot at this point determine whether
SIRT1 deacetylation of PPARg is the only pathway
by which PPARg activity is regulated in the process of
aging.
It has been reported that SIRT1 and p300 can interact
(24,31), and results in this study also support this ﬁnding
(Supplementary Data, Figure 4). Moreover this type of
interaction is similar to those which have been founded
between SIRT1 and protein targets other than p300. For
example, SIRT1 has been observed to bind separately to
both p53 and Foxo3a (9,32–34), and evidence shows that
p53 and Foxo3a can also bind to each other (35). SIRT1
may therefore be an important component of a number of
distinct transcriptional complexes potentially acting as a
scaffold to tether various members of the complex
together. In addition, it is possible that SIRT1 functions
as a bridge, coordinating metabolic status with transcrip-
tion of key target genes with NAD dependent regulation
of the activity of SIRT1.
SA- -gal activity can distinguish senescent cells from
quiescent or terminally differentiated cells and act as a
biomarker of senescent cells (20). Our previous observa-
tions showed that silencing PPARg decreased SA- -gal
activity (14) and SIRT1 overexpression led to a reduction
of SA- -gal activity (15). We want to know whether it
changes senescent-like phenotype (inﬂuenced SA- -gal
activity) when we infect both SIRT1 and PPARgshRNA
or both SIRT1H363Y (dominant-negative form of SIRT1
deacetylase) and PPARgshRNA plasmids into young 2BS
cells. Our results suggested that SIRT1 deacetylase activity
inﬂuenced appearance of senescence-associated features in
2BS cells (Figure 7B).
In summary, our present data show that the
longevity-regulating protein SIRT1 is under the direct
control of PPARg and that the role of SIRT1 in regulating
cellular senescence potentially involves a negative
feedback loop in which both PPARg and SIRT1 partici-
pate as depicted in the model in Figure 8. Various poly-
unsaturated fatty acids, which are the major dietary
constituents, are speciﬁc ligands for PPARg (36) and
SIRT1 catalytic activity can be modulated by NAD and
small molecular organic compounds. Based upon this
model, PPARg and SIRT1 may together engage in a
complex set of circular interactions to ensure that SIRT1
exerts normal homeostatic control of cellular responses in
aging and environmental conditions. Given the capacity
shown by SIRT1 to repress PPARg activity, it is clear that
SIRT1 can provide a novel transcriptional and
posttranscriptional regulation loop for PPARg. Under
normal physiological conditions, PPARg represses
SIRT1 transcription, thereby allowing p300 acetylation
of PPARg to enhance the function of this protein and
promote aging. In addition, SIRT1 may also regulate
PPARg by a combination of PPARg deacetylation and
promoter targeting.
In conclusion, our study demonstrated that activated
PPARg represses SIRT1 gene expression during aging,
in part by deacetylation. Previous research has shown
that fatty acids can inﬂuence the transcriptional activity
of PPARg. In our research, PPARg promoted senescence
by reducing SIRT1 expression in a ligand-dependent
manner and SIRT1 activity can be modulated by NAD
and small molecular organic compounds. The model sug-
gested by our study may offer an opportunity to observe
gene–environment interactions associated with cellular
senescence in health and disease.
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